-$0.39 EPS Expected for Profound Medicl (NYSE:PROF) This Quarter

Equities research analysts expect Profound Medicl (NYSE:PROF) to post earnings per share (EPS) of ($0.39) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Profound Medicl’s earnings. The firm is expected to announce its next earnings results on Thursday, February 6th.

On average, analysts expect that Profound Medicl will report full-year earnings of ($0.84) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($0.23). For the next year, analysts expect that the firm will post earnings of ($0.59) per share, with EPS estimates ranging from ($1.25) to ($0.11). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Profound Medicl.

Profound Medicl (NYSE:PROF) last issued its earnings results on Thursday, November 7th. The company reported ($0.43) earnings per share for the quarter. The company had revenue of $0.52 million during the quarter.

Separately, Echelon Wealth Partners reiterated a “buy” rating on shares of Profound Medicl in a report on Friday, November 8th.

Shares of Profound Medicl stock opened at $9.66 on Monday. Profound Medicl has a twelve month low of $3.69 and a twelve month high of $12.00.

About Profound Medicl

Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease.

Featured Article: What is Compound Interest?

Get a free copy of the Zacks research report on Profound Medicl (PROF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Profound Medicl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medicl and related companies with MarketBeat.com's FREE daily email newsletter.